{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:24:40Z","timestamp":1779143080160,"version":"3.51.4"},"reference-count":120,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019229","name":"ViewRay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011983","name":"American Radium Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ijrobp.2019.06.2544","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T01:57:03Z","timestamp":1562378223000},"page":"591-605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer"],"prefix":"10.1016","volume":"105","author":[{"given":"Suzanne","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilofer","family":"Azad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajnan","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadranka","family":"Dragovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karyn A.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"William","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Warren","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma K.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.06.2544_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.15585\/mmwr.mm6526a1","article-title":"Human papillomavirus-associated cancers - United States, 2008-2012","volume":"65","author":"Viens","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/ijc.24215","article-title":"Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions","volume":"124","author":"Hoots","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: A systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: A\u00a0systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.15585\/mmwr.mm6633a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016","volume":"66","author":"Walker","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/codi.12325","article-title":"Adenocarcinoma of the anal canal - a systematic review","volume":"15","author":"Anwar","year":"2013","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.2008.19.6857","article-title":"US intergroup anal carcinoma trial: Tumor diameter predicts for colostomy","volume":"27","author":"Ajani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.28979","article-title":"Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy","volume":"136","author":"Rodel","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib10","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2013.52.3464","article-title":"Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal","volume":"32","author":"Serup-Hansen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib11","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.18632\/oncotarget.23545","article-title":"The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: A meta-analysis","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib12","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/1097-0142(19840315)53:6<1285::AID-CNCR2820530611>3.0.CO;2-N","article-title":"Epidermoid cancer of the anorectum","volume":"53","author":"Frost","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/codi.12951","article-title":"Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus","volume":"17","author":"Arana","year":"2015","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PGP.0b013e31826916c7","article-title":"The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: Background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"32","author":"Darragh","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.critrevonc.2016.03.001","article-title":"Treatment that follows guidelines closely dramatically improves overall survival of patients with anal canal and margin cancers","volume":"101","author":"Delhorme","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/DCR.0b013e318255815e","article-title":"Practice parameters for anal squamous neoplasms","volume":"55","author":"Steele","year":"2012","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/1097-0142(19950201)75:3<786::AID-CNCR2820750307>3.0.CO;2-3","article-title":"Conservative versus nonconservative treatment of epidermoid carcinoma of the anal canal for tumors longer than or equal to 5 centimeters. A retrospective comparison","volume":"75","author":"Touboul","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/COC.0b013e3181e9c0c0","article-title":"Squamous cell carcinoma of the anal margin: The University of Florida experience","volume":"34","author":"Balamucki","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/DCR.0000000000000050","article-title":"Inguinal lymph node recurrence in the untreated groin of\u00a0patients with anal carcinoma","volume":"57","author":"Blinde","year":"2014","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib22","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2013.07.035","article-title":"Anal carcinoma: Impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial","volume":"87","author":"Gunderson","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib24","doi-asserted-by":"crossref","first-page":"20170370","DOI":"10.1259\/bjr.20170370","article-title":"PET imaging in anal canal cancer: A systematic review and meta-analysis","volume":"90","author":"Mahmud","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib25","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1245\/s10434-015-4391-9","article-title":"The role of FDG-PET in the initial staging and response assessment of anal cancer: A systematic review and meta-analysis","volume":"22","author":"Jones","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib26","first-page":"238","article-title":"Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique","volume":"169","author":"Wade","year":"1989","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib27","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1463-1318.2010.02193.x","article-title":"The role of (1)(8)fluoro-deoxy glucose combined position emission and computed tomography in the clinical management of anal squamous cell carcinoma","volume":"13","author":"Engledow","year":"2011","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijrobp.2011.10.048","article-title":"Role of positron emission tomography-computed tomography in the management of anal cancer","volume":"84","author":"Mistrangelo","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib29","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1007\/s00330-017-5133-0","article-title":"The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal","volume":"28","author":"Prezzi","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib30","first-page":"509","article-title":"Treatment of epidermoid carcinoma of the anal canal","volume":"161","author":"Greenall","year":"1985","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib31","first-page":"629","article-title":"Results of surgical treatment of squamous cell carcinoma of the anal canal and anal margin seen at St. Mark\u2019s Hospital 1928-66","volume":"61","author":"Hardcastle","year":"1968","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00066-012-0120-5","article-title":"Postoperative versus definitive chemoradiation in early-stage anal cancer. Results of a matched-pair analysis","volume":"188","author":"Berger","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/1097-0142(19940315)73:6<1569::AID-CNCR2820730607>3.0.CO;2-F","article-title":"Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients","volume":"73","author":"Touboul","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0167-8140(92)90268-Y","article-title":"The management of carcinoma of the anal canal by external beam radiotherapy, experience in Vancouver 1971-1988","volume":"25","author":"Newman","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/DCR.0000000000001103","article-title":"A population-based cohort analysis of chemoradiation versus radiation alone for definitive treatment of stage I anal cancer in older patients","volume":"61","author":"Buckstein","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/bjs.1800720411","article-title":"Local radiotherapy in the management of squamous carcinoma of the anus","volume":"72","author":"James","year":"1985","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0360-3016(91)90265-6","article-title":"Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C","volume":"21","author":"Cummings","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib38","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/1097-0142(19951115)76:10<1731::AID-CNCR2820761009>3.0.CO;2-H","article-title":"Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study","volume":"76","author":"Martenson","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2011.09.015","article-title":"Node-negative T1-T2 anal cancer: Radiotherapy alone or concomitant chemoradiotherapy?","volume":"102","author":"Zilli","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib40","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib41","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib42","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.clon.2014.03.005","article-title":"Chemoradiotherapy for squamous cell cancer of the anal canal: A systematic review","volume":"26","author":"Spithoff","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib44","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib45","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2012.06.006","article-title":"Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): Long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin","volume":"104","author":"Sebag-Montefiore","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib47","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/j.ijrobp.2011.02.042","article-title":"Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292)","volume":"81","author":"Chakravarthy","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib48","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 x 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib49","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv248","article-title":"Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase III randomized clinical trial","volume":"107","author":"Allegra","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib51","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3332\/ecancer.2016.699","article-title":"Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: Systematic review and meta-analysis","volume":"10","author":"Souza","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u2014a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib53","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2017.03.022","article-title":"Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer","volume":"98","author":"Goodman","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib54","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ijrobp.2018.04.033","article-title":"Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-c and intensity modulated radiation therapy: Evaluation of a national cohort","volume":"101","author":"Jones","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib55","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12029-015-9790-4","article-title":"Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal","volume":"47","author":"Oliveira","year":"2016","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1748-717X-9-124","article-title":"Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma","volume":"9","author":"Thind","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4149\/313_150913N485","article-title":"The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma","volume":"63","author":"Richter","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib59","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijrobp.2016.11.021","article-title":"Significance of co-expression of epidermal growth factor receptor and ki67 on clinical outcome in patients with anal cancer treated with chemoradiotherapy: An analysis of NRG Oncology RTOG 9811","volume":"97","author":"Doll","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.radonc.2015.02.008","article-title":"Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial","volume":"114","author":"Levy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib61","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Results of the UNICANCER ACCORD 16 phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib62","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: A phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib63","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","article-title":"Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: A phase II AIDS Malignancy Consortium trial","volume":"35","author":"Sparano","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib64","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1002\/cncr.31721","article-title":"Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study","volume":"124","author":"Elson","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib65","doi-asserted-by":"crossref","first-page":"618","DOI":"10.21037\/jgo.2018.05.07","article-title":"Impact of intensity modulated radiation therapy on survival in anal cancer","volume":"9","author":"Jhaveri","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijrobp.2017.01.006","article-title":"The impact of intensity modulated radiation therapy on hospitalization outcomes in the SEER-Medicare population with anal squamous cell carcinoma","volume":"98","author":"Pollom","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib67","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijrobp.2007.12.027","article-title":"Evaluation of planned treatment breaks during radiation therapy for anal cancer: Update of RTOG 92-08","volume":"72","author":"Konski","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib70","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.prro.2012.02.005","article-title":"Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center","volume":"3","author":"Call","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib71","first-page":"70","article-title":"Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in\u00a0carcinoma of anal canal: a prospective study","volume":"4","author":"Rattan","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib72","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib73","first-page":"368","article-title":"Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"29","author":"Kachnic","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib74","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.critrevonc.2018.03.013","article-title":"Positron emission tomography and computed tomographic (PET\/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis","volume":"126","author":"Albertsson","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13014-017-0883-z","article-title":"Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography","volume":"12","author":"Rusten","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib76","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: A Radiation Therapy Oncology Group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib77","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib78","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.clon.2014.08.001","article-title":"Anal cancer: Developing an intensity-modulated radiotherapy solution for ACT2 fractionation","volume":"26","author":"Muirhead","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib79","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: A pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib80","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.ejca.2009.06.020","article-title":"Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)","volume":"45","author":"Matzinger","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib81","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijrobp.2017.02.005","article-title":"Predictors of radiation therapy-related gastrointestinal toxicity from anal cancer dose-painted intensity modulated radiation therapy: Secondary analysis of NRG Oncology RTOG 0529","volume":"98","author":"Olsen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib82","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13014-018-1124-9","article-title":"Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: Results of a retrospective observational study","volume":"13","author":"Franco","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib83","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00066-014-0628-y","article-title":"Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series","volume":"190","author":"Lestrade","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib84","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.ijrobp.2012.09.034","article-title":"Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study)","volume":"85","author":"Moureau-Zabotto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib85","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5114\/jcb.2018.76884","article-title":"Brachytherapy boost after chemoradiation in anal cancer: A systematic review","volume":"10","author":"Frakulli","year":"2018","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib86","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/1097-0142(19830415)51:8<1378::AID-CNCR2820510810>3.0.CO;2-F","article-title":"Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases","volume":"51","author":"Flam","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib87","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3748\/wjg.v13.i6.895","article-title":"Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal","volume":"13","author":"Huang","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib88","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0167-8140(93)90076-K","article-title":"Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin","volume":"27","author":"Rich","year":"1993","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib89","first-page":"33446","article-title":"Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03)","volume":"S0167-8140","author":"Faivre","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1055-3207(18)30414-9","article-title":"Anal squamous cell cancer nodal metastases: Prognostic significance and therapeutic considerations","volume":"5","author":"Cohen","year":"1996","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib91","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2013.03.008","article-title":"Elective inguinal node irradiation in early-stage T2N0 anal cancer: Prognostic impact on locoregional control","volume":"87","author":"Zilli","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib92","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ijrobp.2011.02.010","article-title":"Anal canal cancer: Management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study)","volume":"82","author":"Ortholan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib93","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00432-018-2608-6","article-title":"Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients","volume":"144","author":"De Bari","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib94","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00066-015-0885-4","article-title":"Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: Back to the roots?","volume":"191","author":"Henkenberens","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2015.07.050","article-title":"Evaluation of a 36 Gy elective node irradiation dose in anal cancer","volume":"116","author":"Lepinoy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib96","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ijrobp.2017.09.034","article-title":"Effect of CD4 count on treatment toxicity and tumor recurrence in human immunodeficiency virus-positive patients with anal cancer","volume":"100","author":"Bryant","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib97","first-page":"1634","article-title":"Management of anal cancer in the HIV-positive population","volume":"19","author":"Kauh","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib98","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): A post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib99","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1245\/s10434-006-9221-7","article-title":"Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal","volume":"14","author":"Mullen","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib100","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1245\/s10434-007-9491-8","article-title":"Outcomes of salvage surgery for squamous cell carcinoma of the anal canal","volume":"14","author":"Schiller","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib101","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/MNM.0000000000000560","article-title":"Negative 18F-FDG-PET-CT may exclude residual or\u00a0recurrent disease in anal cancer","volume":"37","author":"Teagle","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib102","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/bjs.4908","article-title":"Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer","volume":"92","author":"Renehan","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib103","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1245\/s10434-018-6483-9","article-title":"Salvage abdominoperineal resection for squamous cell anal cancer: A 30-year single-institution experience","volume":"25","author":"Hagemans","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib104","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.amjsurg.2011.01.015","article-title":"Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment","volume":"201","author":"Eeson","year":"2011","journal-title":"Am J Surg"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib105","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.ejso.2018.06.016","article-title":"30-day and long-term outcome following salvage surgery for squamous cell carcinoma of the anus","volume":"44","author":"Pedersen","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib106","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1245\/s10434-015-4545-9","article-title":"Interstitial brachytherapy for the treatment of locally recurrent anorectal cancer","volume":"22","author":"Bishop","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib107","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11912-018-0698-6","article-title":"Systemic Therapies for Advanced Squamous Cell Anal Cancer","volume":"20","author":"Sclafani","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib108","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40265-017-0792-3","article-title":"Pharmacotherapy of anal cancer","volume":"77","author":"Rogers","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib109","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1634\/theoncologist.2016-0241","article-title":"Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients","volume":"22","author":"Sclafani","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib110","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): A multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib111","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib112","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/codi.12474","article-title":"Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer","volume":"16","author":"Sajid","year":"2014","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib113","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/DCR.0000000000001114","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guidelines for anal squamous cell cancers (revised 2018)","volume":"61","author":"Stewart","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib114","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ijrobp.2010.07.1995","article-title":"\u201cMind the gap\u201d\u2014the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I)","volume":"81","author":"Glynne-Jones","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib115","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ijrobp.2018.04.062","article-title":"Association of interim FDG-PET imaging during chemoradiation for squamous anal canal carcinoma with recurrence","volume":"102","author":"Hong","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib116","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.prro.2016.01.004","article-title":"Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma","volume":"6","author":"Goldman","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib117","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/COC.0000000000000343","article-title":"Programmed cell death-ligand 1 (PD-L1) expression in anal cancer","volume":"41","author":"Govindarajan","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S153965","article-title":"Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients","volume":"10","author":"Zhao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib119","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(15)00120-5","article-title":"High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: A prospective observational study","volume":"16","author":"Appelt","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.06.2544_bib120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/SLA.0000000000002447","article-title":"Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: The impact of radiation therapy dose-escalation and consolidation chemotherapy","volume":"269","author":"Habr-Gama","year":"2019","journal-title":"Ann Surg"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619334443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619334443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:44:08Z","timestamp":1759743848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619334443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0360301619334443"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.2544","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.2544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}